Letrozole Combination Increases PFS In ER+ and HER2-Negative Breast Cancer
Afinitor Significantly Reduced Tumor Size In TSC-Related Renal Angiomyolipomas
Nexavar Improves PFS In Phase III Trial
Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease
Ibrutinib Produces 68% Overall Response Rate in Phase II Trial
Researchers Uncover Tumors Sensitive to Chemotherapy
Researchers Find Genetic Alterations in Triple-Negative Cancers Following Treatment
Existing HER2 Drugs May Help More In Breast Cancer Treatment
Smoking Intensity and Markers Predict Cancer Aggressiveness
Low Adiponcetin Hormone Levels Linked to Increased Cancer Risk
No Difference in Toxicity Between IMRT and PRT In Medicare Patients
NCI CTEP Approved Trials For the Month of January
FDA Expands Gleevec Indication For Children with Ph+ ALL
Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - In the Headlines: “There’s no one to stand up for NCI right now.”
- Bhattacharya cancels NIH all-hands meeting
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges
